Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2025-03-13 Regulatory Filings
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획승인신청) (혈우병 치료신약 TU7710의 아르메니아 임상 1b상 시험계획(IND) 승인신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (TiumBio) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for approval of a Phase 1b clinical trial for a hemophilia drug (TU7710) in Armenia. This type of disclosure is a standard regulatory requirement for publicly traded companies in Korea to inform shareholders of material business developments. Since it does not fit into specific categories like financial reports, dividends, or board changes, it falls under the 'Regulatory Filings' category.
2025-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously filed stock option grant. It details changes to the number of recipients and the number of shares granted due to employee resignations. This type of filing, which concerns changes to capital structure and equity-based compensation, falls under the category of share issues or capital changes in a regulatory context.
2025-03-12 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by TiumBio. It outlines the date, location, and agenda items (such as financial statement approval, articles of incorporation changes, and director compensation) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of the meeting and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2025-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously filed stock option grant. It details changes to the number of shares and recipients due to employee resignation. In the context of financial filings, reports regarding stock option grants, amendments to those grants, and related corporate governance disclosures that do not fit into specific categories like 'Director's Dealing' or 'Share Issue' are classified as Regulatory Filings (RNS).
2025-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details changes to previously granted stock options, including adjustments to the number of recipients and the total number of shares granted due to employee turnover. This type of disclosure regarding stock option grants and their subsequent amendments is a standard regulatory requirement for listed companies, falling under the category of general regulatory filings.
2025-03-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically a '정정신고' (Correction Report) regarding previously granted stock options. This type of filing relates to changes in capital structure and employee compensation instruments. In the provided classification schema, filings related to share issues, capital changes, and stock-based compensation adjustments are categorized under 'SHA' (Share Issue/Capital Change).
2025-03-12 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.